Published: The New England Journal of Medicine
Date:
Authors: William V Tamborlane, Margarita Barrientos-PĂ©rez, Udi Fainberg, Helle Frimer-Larsen, Mona Hafez, Paula M Hale, Muhammad Y Jalaludin, Margarita Kovarenko, Ingrid Libman, Jane L Lynch, Paturi Rao, Naim Shehadeh, Serap Turan, Daniel Weghuber, Timothy Barrett, Ellipse Trial Investigators
Abstract:
Metformin is the regulatory-approved treatment of choice for most youth with type 2 diabetes early in the disease. However, early loss of glycemic control has been observed with metformin monotherapy. Whether liraglutide added to metformin (with or without basal insulin treatment) is safe and effective in youth with type 2 diabetes is unknown.
Published: The Lancet
Date:
Authors: Richard M Bergenstal 1, Carol Wysham, Leigh Macconell, Jaret Malloy, Brandon Walsh, Ping Yan, Ken Wilhelm, Jim Malone, Lisa E Porter, DURATION-2 Study Group
Abstract:
Most patients with type 2 diabetes begin pharmacotherapy with metformin, but eventually need additional treatment. We assessed the safety and efficacy of once weekly exenatide, a glucagon-like peptide 1 receptor agonist, versus maximum approved doses of the dipeptidyl peptidase-4 inhibitor, sitagliptin, or the thiazolidinedione, pioglitazone, in patients treated with metformin.